Data from European Society for Medical Oncology (ESMO) - Curated by EPG Health - Last updated 17 April 2018

Status

live

Latest update

13-Jul-17

Multiple myeloma accounts for 1% of all cancers and approximately 10% of all haematological malignancies. These updated ESMO Clinical Practice Guidelines cover the diagnosis and pathology/molecular biology, staging and risk assessment and response evaluation of multiple myeloma. Treatment recommendations address front-line treatment of both asymptomatic (smouldering or indolent) and symptomatic myeloma, consolidation, maintenance and treatment of relapsed and refractory disease and follow-up, including a list of major treatment regimens. A new supportive care section addresses issues related to the occurrence of multiple myeloma such as bone disease and spinal cord compression; anaemia, bone marrow failure and infections; and renal failure.

Read full guideline

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Related Content